Finoriq research workspace
Indaptus Therapeutics, Inc. (INDP) SEC Filings & Filing Highlights
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of. Review INDP SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
- Company
- Indaptus Therapeutics, Inc. (INDP)
- Ticker
- INDP
- Market Cap
- $327.1M
- Latest Price
- $2.455
- Industry
- Biotech & Pharma
Indaptus Therapeutics, Inc. (INDP) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Indaptus Therapeutics, Inc. (INDP).
| Event | Form | Date |
|---|---|---|
| Indaptus Therapeutics, Inc.: Securities issuanceThe shares of Common Stock issued in connection with the Purchase Agreement were issued in reliance upon the exemptions from registration a... | 8-K3.02 | 2026-06-24 |
| Indaptus Therapeutics, Inc.: Material agreementOn June 17, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with certa... | 8-K1.01 | 2026-06-24 |
| Resignation of Directors and Officer Effective as of June 5, 2026, Mr. David E. Lazar and Mr. A...Resignation of Directors and Officer Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorsh... | 8-K5.02 | 2026-06-05 |
| Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 8-K2.02 | 2026-05-15 |
| Appointment of Directors On April 17, 2026, the Board of Directors (the “Board”) of Indaptus Th...Appointment of Directors On April 17, 2026, the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) appointed M... | 8-K5.02 | 2026-04-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.